Does India's AYUSH Push for Global Recognition Actually Have the Evidence and Standards to Back It Up?

India's AYUSH sector — the government-recognised cluster of Ayurveda, Yoga and Naturopathy, Unani, Siddha, and Homeopathy — has been formally embedded in bilateral health agreements with Oman, New Zealand, and the European Union, making it one of the most diplomatically active traditional-medicine systems in the world. Yet a growing chorus of researchers, clinicians, and regulators argues that the sector's global ambitions are running ahead of the evidence base, quality infrastructure, and safety oversight needed to satisfy increasingly stringent international markets.

The gap is not trivial. The World Health Organization's Traditional Medicine Strategy 2025–2034 explicitly calls for member states to integrate traditional medicine through "evidence-based policy, quality assurance, and safety monitoring" — a standard that AYUSH's current regulatory architecture only partially meets. Understanding where the shortfalls lie, and what is genuinely being done to close them, matters both for policymakers and for the millions of consumers worldwide already purchasing Ayurvedic, Yoga-adjacent, and herbal products marketed under the AYUSH banner.

AYUSH at a Glance: Diplomatic Reach vs. Regulatory Readiness

The table below maps the key dimensions of AYUSH's global push against the current state of play, drawing on expert assessments reported by The Hindu and publicly available regulatory data.

Dimension	Diplomatic/Policy Status	Current Gaps Identified by Experts
Clinical Evidence	AYUSH featured in MoUs with Oman, New Zealand, EU	Most flagship herbs lack large-scale RCTs meeting ICH or CONSORT standards
Quality & Standardisation	Pharmacopoeial standards exist for ~600 Ayurvedic formulations	No internationally harmonised GMP framework aligned with EU/US/WHO norms
Regulation & Oversight	Ministry of AYUSH established 2014; CDSCO oversight partial	Ayurvedic drugs regulated under Drugs & Cosmetics Act 1940 — pre-dates modern pharmacovigilance
Practitioner Quality	~800,000 registered AYUSH practitioners in India	Curriculum, clinical training hours, and competency assessments vary widely by state
Patient Safety	National Pharmacovigilance Programme for ASU&H drugs exists	Adverse event reporting rates remain low; heavy-metal content in some formulations flagged by EU/US regulators
Global Market Access	Yoga widely accepted; Ayurvedic products exported to 100+ countries	EU Novel Food Regulation, US FDA dietary supplement rules, and TGA (Australia) create market-entry barriers

What exactly is AYUSH, and why is India promoting it internationally?

AYUSH is the collective term for six traditional and alternative medicine systems formally recognised by the Indian government: Ayurveda, Yoga and Naturopathy, Unani, Siddha, and Homeopathy. A dedicated Ministry of AYUSH was carved out of the Ministry of Health in November 2014, signalling a strategic elevation of these systems from peripheral to mainstream health policy.

The diplomatic rationale is layered. India's AYUSH exports — including herbal formulations, essential oils, and nutraceuticals — were valued at approximately ₹14,000 crore (roughly USD 1.7 billion) in 2022–23, and the government has set an aspirational target of ₹1 lakh crore by 2030. Yoga, which sits within the AYUSH umbrella, already commands near-universal global recognition following the United Nations' designation of June 21 as International Day of Yoga in 2015. Embedding AYUSH in bilateral agreements with Oman, New Zealand, and the EU is therefore partly an economic play — opening regulated markets to Indian herbal products — and partly a soft-power exercise, positioning India as the custodian of an ancient healing tradition with contemporary relevance.

The agreements themselves typically cover joint research, mutual recognition of practitioners, facilitation of product registration, and collaborative clinical trials. On paper, this is a sensible framework. The problem, as The Hindu reports, is that the evidentiary and regulatory infrastructure needed to make those commitments meaningful is still being built.

Does AYUSH have credible clinical evidence behind its key therapies?

This is the question that most sharply divides proponents and critics, and the honest answer is: it depends heavily on which therapy and which outcome you are asking about.

Yoga sits at one end of the spectrum. The evidence base for yoga's benefits on stress, anxiety, hypertension, and musculoskeletal pain is now substantial enough that systematic reviews and meta-analyses have appeared in journals including The Lancet, JAMA Internal Medicine, and Annals of Internal Medicine. The WHO's 2019 Global Action Plan on Physical Activity explicitly acknowledges yoga as a health-promoting practice. This is the part of AYUSH's portfolio that faces the least international resistance.

Ayurveda occupies a more contested middle ground. Individual botanicals prominent in Ayurvedic practice — ashwagandha (Withania somnifera), turmeric/curcumin, Boswellia serrata, and Tinospora cordifolia — have been studied in randomised controlled trials (RCTs) with varying degrees of rigour. Ashwagandha's adaptogenic and cortisol-modulating effects have been replicated across multiple small-to-medium RCTs. Curcumin's anti-inflammatory properties are well-documented, though bioavailability remains a formulation challenge — a topic covered in detail in our Best Curcumin Supplements for Joint Health in India guide. Arjuna (Terminalia arjuna) has a growing body of cardiac research, though as we note in our Arjuna for Heart Health in India article, single-herb evidence rarely translates cleanly into multi-herb classical formulations.

The deeper problem is that most Ayurvedic practice does not involve single, standardised botanical extracts studied in isolation. It involves complex polyherbal formulations, individualised prescriptions, dietary modifications, and lifestyle interventions delivered by a practitioner — a therapeutic model that is genuinely difficult to evaluate using the double-blind RCT design that regulators in the EU, US, and Australia treat as the gold standard. This is not a uniquely Ayurvedic problem; traditional Chinese medicine and Kampo face the same methodological tension. But it does mean that the evidence gap is structural, not merely a funding shortfall that can be closed in a few years.

Homeopathy, which sits within the AYUSH umbrella, is a different matter. The scientific consensus — reflected in systematic reviews by the Australian National Health and Medical Research Council, the UK's House of Commons Science and Technology Committee, and numerous Cochrane reviews — is that homeopathy performs no better than placebo for any health condition. Bundling homeopathy into the same diplomatic package as yoga and evidence-supported Ayurvedic botanicals creates a credibility problem for the entire AYUSH brand in markets where regulators and consumers are evidence-literate.

Unani and Siddha have even thinner modern evidence bases than Ayurveda, largely because research investment in these systems has been lower and the practitioner communities smaller.

Are AYUSH quality and manufacturing standards good enough for global markets?

Quality standardisation — establishing and enforcing consistent specifications for the identity, purity, potency, and safety of a product — is where AYUSH faces its most concrete and immediately solvable challenges.

India does have pharmacopoeial infrastructure. The Ayurvedic Pharmacopoeia of India (API) and the Ayurvedic Formulary of India (AFI) together cover several hundred single drugs and compound formulations, specifying botanical identity, physicochemical parameters, and in some cases microbial limits. The Pharmacopoeial Laboratory for Indian Medicine (PLIM) conducts quality testing. Good Manufacturing Practice (GMP) certification under Schedule T of the Drugs & Cosmetics Act is mandatory for licensed Ayurvedic manufacturers.

The gap emerges when Indian standards are compared with the requirements of target export markets:

The European Union's Novel Food Regulation (EU 2015/2283) requires a safety assessment for any food ingredient not in common use in the EU before 1997. Many Ayurvedic botanicals fall into this category, meaning they cannot be legally marketed as food supplements in the EU without prior authorisation — a process that requires toxicological dossiers that most Indian manufacturers have not compiled.
The US FDA's dietary supplement framework under DSHEA 1994 is more permissive than the EU's, but it still requires Current Good Manufacturing Practice (cGMP) compliance, and the FDA has issued warning letters to Indian Ayurvedic product exporters for heavy-metal contamination (lead, mercury, arsenic) and adulteration.
Australia's TGA classifies most Ayurvedic products as complementary medicines and requires listed or registered product status, with mandatory evidence of safety and, for registered products, efficacy.

The heavy-metal issue deserves particular attention. A subset of classical Ayurvedic formulations — known as rasa shastra preparations — deliberately incorporate processed metals and minerals, including mercury (as parada), lead (naga), and arsenic (hartala). Proponents argue that traditional purification processes (shodhana) render these safe; toxicologists in the EU, US, and Australia are not convinced, and regulatory agencies in those markets have repeatedly seized or recalled Ayurvedic products with heavy-metal levels exceeding permitted limits. This is not a fringe issue: a 2008 study in JAMA found that approximately 20% of Ayurvedic medicines manufactured in the US and India and sold via the internet contained detectable levels of lead, mercury, or arsenic.

India's response has been to tighten domestic heavy-metal limits and invest in testing infrastructure, but the gap between domestic permissible levels and those in EU/US/Australian markets remains significant. Until it is closed, heavy-metal contamination will remain the single biggest barrier to Ayurvedic product exports in regulated markets.

How does AYUSH regulation compare with international frameworks?

AYUSH regulation — the legal and administrative framework governing the manufacture, sale, quality, and clinical use of AYUSH products and services in India — is a patchwork that has evolved incrementally rather than by design.

The primary legislation is the Drugs & Cosmetics Act of 1940, which predates modern concepts of pharmacovigilance, post-market surveillance, and evidence-based licensing. Ayurvedic drugs are regulated under Schedule E and the related rules, but the licensing authority is the state government, not the central government — creating significant inter-state variation in enforcement. A manufacturer in one state may face rigorous GMP inspections; a manufacturer in another may not.

The Ministry of AYUSH has attempted to modernise this framework through several initiatives:

The Pharmacovigilance Programme for Ayurveda, Siddha, Unani and Homeopathy (PvPI-ASU&H), launched in 2015, aims to collect adverse drug reaction (ADR) reports from AYUSH practitioners and hospitals. Reporting rates, however, remain far below those seen in the allopathic pharmacovigilance system, partly because AYUSH practitioners are not always trained in ADR recognition and partly because the cultural assumption that "natural" means "safe" suppresses reporting.
The AYUSH Premium Mark scheme, launched in 2021, is intended to certify high-quality AYUSH products for export. Its international recognition is, as yet, limited.
The National AYUSH Mission funds state-level infrastructure, including AYUSH hospitals and dispensaries, but does not directly address the regulatory harmonisation gap with export markets.

Internationally, the WHO's Traditional Medicine Strategy 2025–2034 provides a framework, and India has been active in WHO's work on traditional medicine benchmarks. The WHO has published benchmarks for training in Ayurveda, and India has used these in its bilateral agreements. WHO benchmarks are non-binding, however, and the EU, US, and Australian regulators operate under their own statutory frameworks that do not automatically defer to WHO guidance on traditional medicine.

What about practitioner quality and patient safety?

Practitioner quality — the extent to which a healthcare provider possesses and applies the knowledge, skills, and professional behaviours required to deliver safe and effective care — is an area where AYUSH faces significant internal heterogeneity.

India has approximately 800,000 registered AYUSH practitioners, trained through a network of around 700 AYUSH colleges offering the Bachelor of Ayurvedic Medicine and Surgery (BAMS), Bachelor of Unani Medicine and Surgery (BUMS), Bachelor of Siddha Medicine and Surgery (BSMS), and Bachelor of Homeopathic Medicine and Surgery (BHMS) degrees. These are five-and-a-half-year programmes including a one-year internship — comparable in duration to MBBS.

The quality problem is not primarily one of programme length but of programme content and clinical training infrastructure. A 2019 report by the Parliamentary Standing Committee on Health and Family Welfare noted wide variation in the quality of AYUSH colleges, inadequate clinical training facilities in many institutions, and a shortage of qualified faculty. Some states have a proliferation of private AYUSH colleges with minimal infrastructure, admitted under relaxed norms. The result is a practitioner workforce of highly variable competence.

This matters for patient safety in two ways. A poorly trained AYUSH practitioner may fail to recognise a serious condition requiring allopathic intervention, leading to diagnostic delay. A poorly trained practitioner may also prescribe formulations containing heavy metals or herb-drug interactions without adequate monitoring. The risk of herb-drug interactions is particularly relevant as more patients use AYUSH products alongside conventional medications — a pattern that is common but poorly documented. Tinospora cordifolia (guduchi), for instance, has immunomodulatory effects that could theoretically interact with immunosuppressant drugs; ashwagandha has thyroid-stimulating properties that may be relevant in patients on thyroid medication.

Patient safety infrastructure in AYUSH is improving but remains thin. The PvPI-ASU&H programme is a genuine step forward, but its coverage is limited. There is no mandatory adverse event reporting system for AYUSH practitioners equivalent to the Yellow Card scheme in the UK or MedWatch in the US. Post-market surveillance of AYUSH products is less systematic than for allopathic drugs.

What do international markets actually require before accepting AYUSH products?

The regulatory requirements of India's key target markets are worth understanding in concrete terms, because they set the bar that AYUSH must clear.

In the European Union, the Traditional Herbal Medicinal Products Directive (THMPD, 2004/24/EC) created a simplified registration pathway for traditional herbal medicines with at least 30 years of traditional use, including 15 years in the EU. This pathway requires proof of traditional use, quality dossiers meeting EU GMP standards, and safety data — but not efficacy trials. The catch for Ayurvedic products is the 15-year EU use requirement, which most Indian botanicals do not meet, pushing them into the Novel Food Regulation pathway instead, which is more demanding. As of 2024, only a handful of Ayurvedic single-herb preparations have been successfully registered under the THMPD in any EU member state.

In the United States, the DSHEA framework is more accommodating in principle — dietary supplements do not require pre-market approval — but the cGMP requirements are stringent, and the FDA's enforcement actions against adulterated and misbranded Ayurvedic products have been significant. The US market for Ayurvedic products is growing, but it is dominated by companies that have invested in US-compliant manufacturing and third-party testing, not by traditional Indian manufacturers.

In New Zealand and Australia, the regulatory frameworks (Medsafe and TGA respectively) require complementary medicine products to meet safety and quality standards, with efficacy evidence required for therapeutic claims. The MoU between India and New Zealand on AYUSH cooperation is a framework agreement, not a mutual recognition of products — actual market access still requires compliance with New Zealand's Medicines Act and associated regulations.

This is the core tension that experts are pressing India to address: diplomatic agreements create frameworks and goodwill, but they do not substitute for the technical work of regulatory harmonisation, evidence generation, and quality infrastructure investment.

What is actually being done to close the gap?

Several initiatives deserve acknowledgment.

The All India Institute of Ayurveda (AIIA) in New Delhi is a centre of excellence for Ayurvedic clinical research and has published peer-reviewed studies in indexed journals. The Central Council for Research in Ayurvedic Sciences (CCRAS) has a portfolio of clinical trials, though critics note that many are small, lack blinding, and are not registered prospectively on CTRI (India's clinical trial registry) — a prerequisite for publication in high-impact journals.

The AYUSH-CSIR collaboration has produced some pharmacological and phytochemical research of genuine quality. During the COVID-19 pandemic, the CSIR-AYUSH collaboration on Coronil (a Patanjali product) became a flashpoint precisely because the evidence standards applied were perceived as lower than those applied to allopathic COVID-19 treatments — a perception that damaged AYUSH's credibility among the scientific community.

India has also been active in the WHO's International Classification of Traditional Medicine (ICTM) project, which aims to create a standardised terminology for traditional medicine diagnoses and interventions. This is genuinely useful infrastructure for future research and regulatory harmonisation. The AYUSH Premium Mark and the India Organic certification for herbal raw materials are steps toward quality signalling in export markets, though their international recognition remains limited.

What is missing is a coherent, time-bound roadmap that links diplomatic ambitions to specific regulatory milestones: harmonising heavy-metal limits with EU/US standards by a given date, registering a defined number of Ayurvedic products under the EU THMPD by a given date, publishing a defined number of prospectively registered RCTs in indexed journals by a given date. Without such a roadmap, the gap between AYUSH's diplomatic profile and its evidentiary standing will persist.

What should consumers and practitioners make of AYUSH products right now?

For consumers in India and globally who are already using or considering AYUSH products — whether Ayurvedic supplements, herbal formulations, or yoga-based wellness programmes — the picture is detailed rather than binary.

Yoga has a solid evidence base for specific outcomes and carries minimal safety risk when practised appropriately. It is the most defensible component of the AYUSH portfolio from an evidence standpoint, and its global uptake reflects genuine value.

For Ayurvedic botanicals, the evidence varies by compound. Ashwagandha, curcumin, Boswellia, and Triphala have meaningful research behind them, though the quality of that research is uneven. Consumers should look for products that specify the botanical species, the part of the plant used, the extraction method, and the concentration of active compounds — and ideally carry third-party testing certification for heavy metals and microbial contaminants. Our guides on Ayurvedic supplements for acne and Berberine for insulin resistance illustrate how to apply this kind of evidence-based lens to specific conditions.

For complex polyherbal formulations, classical rasa shastra preparations, and any AYUSH product making specific therapeutic claims, the evidence bar is higher and the safety considerations more complex. Patients with chronic conditions, those on prescription medications, and those who are pregnant or immunocompromised should consult a qualified practitioner — ideally one trained in both AYUSH and conventional medicine — before using such products.

Homeopathy, as the scientific consensus stands, should not be used as a substitute for evidence-based treatment for any serious condition.

What would "credible standards" actually look like for AYUSH?

Experts quoted in The Hindu's reporting press for credible standards across five dimensions. Translating that into concrete benchmarks:

Evidence: A credible AYUSH evidence standard would require prospective registration of all clinical trials on CTRI, adherence to CONSORT reporting guidelines, independent peer review in indexed journals, and systematic reviews commissioned by CCRAS and published openly. For priority conditions — metabolic syndrome, osteoarthritis, anxiety, respiratory infections — India should fund adequately powered, multi-centre RCTs with pre-specified primary endpoints.

Quality: Harmonising Indian GMP standards with WHO GMP guidelines for herbal medicines, and progressively aligning heavy-metal limits with EU/US standards, would remove the most significant barrier to export market access. Third-party testing by accredited laboratories should be mandatory for export products, with certificates of analysis publicly available.

Regulation: Centralising AYUSH drug licensing at the national level, modernising the Drugs & Cosmetics Act provisions for AYUSH, and strengthening the PvPI-ASU&H to achieve mandatory ADR reporting from all licensed AYUSH practitioners would substantially improve the regulatory framework.

Practitioner quality: Implementing a national competency framework for AYUSH practitioners, with minimum clinical training hours, standardised assessments, and mandatory continuing professional development, would reduce the quality variance that currently undermines trust in the practitioner workforce.

Patient safety: Establishing a mandatory adverse event reporting system for AYUSH products and practitioners, with public disclosure of safety signals, would align India with international pharmacovigilance norms and build the trust of foreign regulators.

None of these steps is technically impossible. Several are already partially underway. The question is whether the political will exists to prioritise regulatory rigour over diplomatic optics — to build the foundation that would make AYUSH's global ambitions genuinely sustainable.

The bottom line

India's AYUSH push for global recognition is not without foundation. Yoga has earned its place in the global health conversation on evidence. Several Ayurvedic botanicals have a meaningful and growing research base. India's traditional medicine heritage is real, and the WHO's own strategy supports the integration of traditional medicine into health systems — provided it is done through evidence-based policy, quality assurance, and safety monitoring.

The gap between AYUSH's current diplomatic profile and the evidentiary and regulatory standards demanded by the EU, US, Australia, and New Zealand is nonetheless real and significant. Heavy-metal contamination, inconsistent GMP compliance, thin evidence for complex formulations, variable practitioner quality, and the inclusion of homeopathy in the same policy umbrella all create credibility risks that diplomatic agreements cannot paper over.

The experts pressing for credible standards are not opponents of traditional medicine. They are making the case that AYUSH's long-term global success depends on meeting the same evidence and safety bar that any health intervention must meet in regulated markets. That is a harder path than signing MoUs, but it is the only path that leads to durable recognition.

For consumers navigating this space, the practical implication is to apply the same evidence-based scrutiny to AYUSH products that you would apply to any supplement or health intervention — looking for standardised extracts, third-party testing, and peer-reviewed evidence for specific claims, rather than accepting traditional use or diplomatic endorsement as a substitute for rigorous evaluation. Our Best Health Supplements to Take in India (2026) guide offers a starting framework for that kind of evaluation.